CA2585779C - In-situ forming implant for animals - Google Patents

In-situ forming implant for animals Download PDF

Info

Publication number: CA2585779C
Authority: CA; Canada
Prior art keywords: composition; composition according; release; polymer; solvent
Prior art date: 2004-12-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2585779A

Other languages

English (en)

French (fr)

Other versions

CA2585779A1 (en

Inventor

Caroline Sautter

Ute Isele

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Elanco Tiergesundheit AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-14

Filing date

2005-12-13

Publication date

2014-01-28

2005-12-13 Application filed by Novartis AG filed Critical Novartis AG

2006-06-22 Publication of CA2585779A1 publication Critical patent/CA2585779A1/en

2014-01-28 Application granted granted Critical

2014-01-28 Publication of CA2585779C publication Critical patent/CA2585779C/en

2025-12-13 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

241001465754 Metazoa Species 0.000 title claims abstract description 19
239000007943 implant Substances 0.000 title claims abstract description 15
238000011065 in-situ storage Methods 0.000 title claims description 11
239000000203 mixture Substances 0.000 claims abstract description 81
229920001169 thermoplastic Polymers 0.000 claims abstract description 24
239000013543 active substance Substances 0.000 claims abstract description 15
230000000975 bioactive effect Effects 0.000 claims description 37
239000000463 material Substances 0.000 claims description 35
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
229940079593 drug Drugs 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 28
239000002671 adjuvant Substances 0.000 claims description 23
239000002904 solvent Substances 0.000 claims description 21
239000003960 organic solvent Substances 0.000 claims description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
239000007787 solid Substances 0.000 claims description 13
235000011187 glycerol Nutrition 0.000 claims description 10
238000013270 controlled release Methods 0.000 claims description 8
229920000747 poly(lactic acid) Polymers 0.000 claims description 8
210000001124 body fluid Anatomy 0.000 claims description 7
239000010839 body fluid Substances 0.000 claims description 7
239000012736 aqueous medium Substances 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 6
229940074076 glycerol formal Drugs 0.000 claims description 6
239000004626 polylactic acid Substances 0.000 claims description 5
239000012530 fluid Substances 0.000 claims description 4
150000005691 triesters Chemical class 0.000 claims description 4
206010072064 Exposure to body fluid Diseases 0.000 claims description 3
230000000895 acaricidal effect Effects 0.000 claims description 3
239000000642 acaricide Substances 0.000 claims description 3
235000019441 ethanol Nutrition 0.000 claims description 3
239000002917 insecticide Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 4
235000013773 glyceryl triacetate Nutrition 0.000 claims 2
229960002622 triacetin Drugs 0.000 claims 2
239000007788 liquid Substances 0.000 abstract description 29
238000012377 drug delivery Methods 0.000 abstract description 7
239000003795 chemical substances by application Substances 0.000 abstract description 6
229920000642 polymer Polymers 0.000 description 31
239000011159 matrix material Substances 0.000 description 16
-1 polyorthocarbonates Polymers 0.000 description 12
238000009472 formulation Methods 0.000 description 11
238000000034 method Methods 0.000 description 10
241000282472 Canis lupus familiaris Species 0.000 description 9
229920001577 copolymer Polymers 0.000 description 8
239000012867 bioactive agent Substances 0.000 description 7
230000036765 blood level Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
239000004014 plasticizer Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000004416 thermosoftening plastic Substances 0.000 description 4
QBBTZXBTFYKMKT-UHFFFAOYSA-N 2,3-diacetyloxypropyl acetate Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O.CC(=O)OCC(OC(C)=O)COC(C)=O QBBTZXBTFYKMKT-UHFFFAOYSA-N 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000007794 irritation Effects 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001112 coagulating effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
229920001281 polyalkylene Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000000979 retarding effect Effects 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
229940093475 2-ethoxyethanol Drugs 0.000 description 1
OMIHCBSQSYMFDP-UHFFFAOYSA-N 3-hydroxy-5-methoxy-3-methoxycarbonyl-5-oxopentanoic acid Chemical compound COC(=O)CC(O)(CC(O)=O)C(=O)OC OMIHCBSQSYMFDP-UHFFFAOYSA-N 0.000 description 1
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 description 1
MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
229930015421 benzophenanthridine alkaloid Natural products 0.000 description 1
150000008622 benzophenanthridines Chemical class 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
244000309464 bull Species 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000003975 dentin desensitizing agent Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
229960001826 dimethylphthalate Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
BDWFYHUDXIDTIU-UHFFFAOYSA-N ethanol;propane-1,2,3-triol Chemical compound CCO.OCC(O)CO BDWFYHUDXIDTIU-UHFFFAOYSA-N 0.000 description 1
229940116333 ethyl lactate Drugs 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000004041 inotropic agent Substances 0.000 description 1
238000002386 leaching Methods 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000003547 miosis Effects 0.000 description 1
239000003604 miotic agent Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
150000003901 oxalic acid esters Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
229920000141 poly(maleic anhydride) Polymers 0.000 description 1
229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
239000000622 polydioxanone Substances 0.000 description 1
229920006149 polyester-amide block copolymer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001855 polyketal Polymers 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000003900 succinic acid esters Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013269 sustained drug release Methods 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
229920001897 terpolymer Polymers 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229920005992 thermoplastic resin Polymers 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
150000003628 tricarboxylic acids Chemical class 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003021 water soluble solvent Substances 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

CA2585779A 2004-12-14 2005-12-13 In-situ forming implant for animals Expired - Fee Related CA2585779C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04029498		2004-12-14
EP04029498.5		2004-12-14
PCT/EP2005/013377 WO2006063794A1 (en)	2004-12-14	2005-12-13	In-situ forming implant for animals

Publications (2)

Publication Number	Publication Date
CA2585779A1 CA2585779A1 (en)	2006-06-22
CA2585779C true CA2585779C (en)	2014-01-28

Family

ID=34927750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2585779A Expired - Fee Related CA2585779C (en)	2004-12-14	2005-12-13	In-situ forming implant for animals

Country Status (16)

Country	Link
JP (1)	JP5372378B2 (es)
KR (1)	KR101304160B1 (es)
CN (1)	CN101056617B (es)
AR (1)	AR052155A1 (es)
AT (1)	ATE389386T1 (es)
AU (1)	AU2005315823B2 (es)
BR (1)	BRPI0519022A2 (es)
CA (1)	CA2585779C (es)
DE (1)	DE602005005522T2 (es)
ES (1)	ES2301084T3 (es)
MX (1)	MX2007007099A (es)
NZ (1)	NZ554904A (es)
RU (1)	RU2394558C2 (es)
TW (1)	TWI369218B (es)
WO (1)	WO2006063794A1 (es)
ZA (1)	ZA200703506B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
WO2008153611A2 (en)	2007-05-25	2008-12-18	Qlt Usa, Inc.	Sustained delivery formulations of risperidone compounds
CN101159064B (zh)	2007-11-29	2010-09-01	腾讯科技（深圳）有限公司	画像生成系统以及按照图像生成画像的方法
US9877973B2 (en)	2008-05-12	2018-01-30	University Of Utah Research Foundation	Intraocular drug delivery device and associated methods
US10588855B2 (en)	2008-05-12	2020-03-17	University Of Utah Research Foundation	Intraocular drug delivery device and associated methods
US10064819B2 (en)	2008-05-12	2018-09-04	University Of Utah Research Foundation	Intraocular drug delivery device and associated methods
JP6543431B2 (ja) *	2013-10-10	2019-07-10	ユニバーシティーオブユタリサーチファウンデーションＵｎｉｖｅｒｓｉｔｙｏｆＵｔａｈＲｅｓｅａｒｃｈＦｏｕｎｄａｔｉｏｎ	眼内薬物送達デバイスおよび付随する方法
ES2971223T3 (es)	2017-04-13	2024-06-04	Ceva Sante Animale	Implante para tratar infestaciones por parasitos
CN112336682B (zh) *	2020-09-28	2022-07-08	浙江大学	具有缓控释药物作用的可注射复合载体与组合物及制备方法
CN119677500A (zh)	2022-06-30	2025-03-21	维克公司	德舍瑞林在与pk/pd相互作用相关的非人类哺乳动物化学去势中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4938763B1 (en) *	1988-10-03	1995-07-04	Atrix Lab Inc	Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) *	1989-07-24	1994-06-28	Atrix Laboratories, Inc.	Biodegradable polymer composition
WO1998027962A2 (en) *	1996-12-20	1998-07-02	Alza Corporation	Injectable depot gel composition and method of preparing the composition
DE69917224T2 (de) *	1998-02-23	2004-09-09	Massachusetts Institute Of Technology, Cambridge	Bioabbaubare polymere mit formgedächtnis
NZ506415A (en) *	1998-03-19	2003-06-30	Merck & Co Inc	Liquid polymeric compositions for controlled release of bioactive substances using a polymer to active agent ratio of less than 1:1
US7128927B1 (en) *	1998-04-14	2006-10-31	Qlt Usa, Inc.	Emulsions for in-situ delivery systems
JP4317606B2 (ja) *	1998-09-18	2009-08-19	サンスター株式会社	固体粒子形成用組成物
RU2355385C2 (ru) *	2002-11-06	2009-05-20	Алза Корпорейшн	Композиции пролонгированного действия с контролируемым высвобождением
JP2007525429A (ja) *	2003-03-11	2007-09-06	キューエルティーユーエスエー，インコーポレイテッド．	細胞スケジュール依存性抗癌剤のための処方

2005
- 2005-12-12 TW TW094143807A patent/TWI369218B/zh not_active IP Right Cessation
- 2005-12-12 AR ARP050105195A patent/AR052155A1/es unknown
- 2005-12-13 MX MX2007007099A patent/MX2007007099A/es active IP Right Grant
- 2005-12-13 AT AT05815330T patent/ATE389386T1/de not_active IP Right Cessation
- 2005-12-13 KR KR1020077013264A patent/KR101304160B1/ko not_active Expired - Fee Related
- 2005-12-13 CA CA2585779A patent/CA2585779C/en not_active Expired - Fee Related
- 2005-12-13 JP JP2007545931A patent/JP5372378B2/ja not_active Expired - Fee Related
- 2005-12-13 AU AU2005315823A patent/AU2005315823B2/en not_active Ceased
- 2005-12-13 CN CN2005800386792A patent/CN101056617B/zh not_active Expired - Fee Related
- 2005-12-13 ES ES05815330T patent/ES2301084T3/es not_active Expired - Lifetime
- 2005-12-13 WO PCT/EP2005/013377 patent/WO2006063794A1/en not_active Ceased
- 2005-12-13 DE DE602005005522T patent/DE602005005522T2/de not_active Expired - Lifetime
- 2005-12-13 NZ NZ554904A patent/NZ554904A/en not_active IP Right Cessation
- 2005-12-13 BR BRPI0519022-3A patent/BRPI0519022A2/pt not_active IP Right Cessation
- 2005-12-13 RU RU2007126759/15A patent/RU2394558C2/ru not_active IP Right Cessation
2007
- 2007-05-02 ZA ZA200703506A patent/ZA200703506B/xx unknown

Also Published As

Publication number	Publication date
JP5372378B2 (ja)	2013-12-18
CN101056617B (zh)	2012-07-11
MX2007007099A (es)	2007-06-22
KR101304160B1 (ko)	2013-09-04
DE602005005522D1 (de)	2008-04-30
JP2008523131A (ja)	2008-07-03
CA2585779A1 (en)	2006-06-22
NZ554904A (en)	2009-11-27
ATE389386T1 (de)	2008-04-15
BRPI0519022A2 (pt)	2008-12-23
ZA200703506B (en)	2008-09-25
TW200635616A (en)	2006-10-16
AR052155A1 (es)	2007-03-07
TWI369218B (en)	2012-08-01
DE602005005522T2 (de)	2009-04-16
AU2005315823B2 (en)	2009-06-04
WO2006063794A1 (en)	2006-06-22
CN101056617A (zh)	2007-10-17
RU2394558C2 (ru)	2010-07-20
RU2007126759A (ru)	2009-01-27
ES2301084T3 (es)	2008-06-16
AU2005315823A1 (en)	2006-06-22
KR20070092964A (ko)	2007-09-14

Publication	Publication Date	Title
ES2359973T3 (es)	2011-05-30	Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
EP1484033B1 (en)	2011-02-23	Liquid polymeric compositions for controlled release of bioactive substances
KR101865689B1 (ko)	2018-06-08	부프레노르핀을 포함하는 주입가능한 유동성 조성물
KR102189442B1 (ko)	2020-12-11	소수성 조성물용 생분해성 약물 전달
EP2244752B1 (en)	2011-09-28	Low viscosity liquid polymeric delivery system
US8017144B2 (en)	2011-09-13	Controlled release polymeric compositions of bone growth promoting compounds
JP4599498B2 (ja)	2010-12-15	非ポリマー持続性解離供給システム
ES2272024T3 (es)	2007-04-16	Emulsiones para sistemas de administracion in situ.
JPH05286850A (ja)	1993-11-02	放出を制御されたインプラントに使用する液状混合物、インプラントに好適なポリマーシステム及びそのポリマーシステムを用いた治療方法
WO1996021427A1 (en)	1996-07-18	Liquid polymer delivery system
HU228386B1 (hu)	2013-03-28	Javított hatékonyságú leuprolid polimeres bejuttatására szolgáló készítmények
CA2585779C (en)	2014-01-28	In-situ forming implant for animals
EP1827377B1 (en)	2008-03-19	In-situ forming implant for animals
JP2005538052A (ja)	2005-12-15	注射製剤
PT1484033E (pt)	2011-04-21	Composições poliméricas líquidas para libertação controlada de substâncias bioactivas
HK1150982B (en)	2012-06-01	Low viscosity liquid polymeric delivery system

Legal Events

Date	Code	Title	Description
2010-12-06	EEER	Examination request
2017-01-24	MKLA	Lapsed	Effective date: 20161213